With semaglutide’s patent expiring, generics are set to enter from soon, setting off competition in a fast-growing segment of obesity and diabetes care
The country’s anti-obesity market is headed for a pricing shake-up. A clutch of pharma companies is preparing to launch more affordable versions of blockbuster weight-loss medicines such as Wegovy and Ozempic.
This could significantly alter who can access medical treatment for obesity in India. Until now, such drugs have remained largely confined to affluent urban patients and private clinics, because of their high monthly cost and the need for long-term use.
This could significantly alter who can access medical treatment for obesity in India. Until now, such drugs have remained largely confined to affluent urban patients and private clinics, because of their high monthly cost and the need for long-term use.